Andere talen NRx Pharmaceuticals, Inc.

Aandelen

NRXP

US6294442099

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
3,54 ^USD	+12,74%		+16,45%	-23,04%

18/04	Exchange-Traded Funds, aandelenfutures hoger pre-Bell donderdag in aanloop naar toespraken Fed-beleidsmakers	MT
17/04	NRx Pharmaceuticals, Inc. Kondigt nieuwe gegevens aan over NRX-101 waaruit blijkt dat er geen schade is aan de darm- en vaginaflora in gevalideerde knaagdiermodellen in vergelijking met standaardantibiotica	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock	19/04
NRx Pharmaceuticals Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement	19/04
NRx Pharmaceuticals Receives Notice of Listing Compliance From Nasdaq	18/04
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Fed Policymakers Speeches	18/04
Top Premarket Decliners	18/04
NRx Pharmaceuticals Looking to Sell Shares to Fund General Corporate Activities; Shares Slump Premarket	18/04
NRx Pharmaceuticals Looking to Sell Shares to Fund General Corporate Activities, Working Capital	17/04
NRx Pharmaceuticals, Inc. Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics	17/04
NRx Pharmaceuticals Announces Development of New, Proprietary Formulation of HTX-100	16/04
NRx Pharmaceuticals, Inc. Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)	15/04
NRx Pharmaceuticals Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression	09/04
NRx Pharmaceuticals, Inc. Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression	08/04
NRx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	02/04
NRx Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights	28/03
NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing	28/03
UPDATE, NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024	27/03
NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024	26/03
NRx Pharmaceutical's Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UK	26/03
NRx Pharmaceutical's (NASDAQ:NRXP) Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UK	25/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen NRx Pharmaceuticals, Inc.

Aandelen

NRXP

US6294442099

Andere talen

Filters